Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Karen E. Anderson,D. Stamler,Mat D. Davis,S. A. Factor,Robert A. Hauser,J. Isojärvi,L. F. Jarskog,J. Jimenez-shahed,R. Kumar,Joseph P McEvoy,S. Ochudło,W. G. Ondo,Hubert H. Fernandez
DOI: https://doi.org/10.1016/S2215-0366(17)30236-5
2017-08-01
Abstract:
What problem does this paper attempt to address?